Writing this once so I can stop repeating it across threads. It is about orforglipron, and it is deliberately narrow — everything I am not confident about is marked as such.
Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and oral bioavailability in the tens of percent instead of around one. Phase 2 put it near 14.7% weight loss at 36 weeks on the top dose with a side-effect profile that looks like the injectables.
The caveat that a daily tablet is a daily adherence decision. Weekly injections have an adherence advantage that gets ignored because injections feel like the harder option.
Phase 2: about 14.7% at 36 weeks on 45mg, GI adverse events broadly in line with the injectables, no food-timing requirement.
So the question, as narrowly as I can put it: whether a non-peptide oral agonist can match injectable exposure in practice, or whether the convenience is bought with a lower ceiling. Happy to be told the question itself is wrong.
Dr.SportsMedIN said:Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
Dr.SportsMedIN said:Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…
I read this differently from Dr.SportsMedIN, on substance rather than tone. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAnswering the narrow version, because the broad one does not have a single answer. The manufacturing argument is the underrated one. Peptide synthesis capacity has been the binding constraint on this entire class, and a small molecule is made in ordinary chemical plants. If it holds up in phase 3, the supply and price picture changes more than the efficacy picture does.
VendorMark said:Agreed, and subgroup analyses deserve particular suspicion.
Mine went the same way, slower.